The 36 references in paper B. Chernyak A., E. Kulikov S., I. Trofimenko N., L. Ogorodova M., M. Freidin B., O. Kozina V., P. Selivanova A., Б. Черняк А., Е. Куликов С., И. Трофименко Н., Л. Огородова М., М. Фрейдин Б., О. Козина В., П. Селиванова А. (2014) “Молекулярно–генетические аспекты различных фенотипов хронической обструктивной болезни легких и бронхиальной астмы // Genetic aspects of different phenotypes of COPD and asthma” / spz:neicon:pulmonology:y:2013:i:1:p:5

1
Lopez D., Shibuya K., Rao C. et al.Chronic obstructive pul$ monary disease: current burden and future projections. Eur. Respir. J. 2006; 27 (2): 397–412.
(check this in PDF content)
2
Holgate S.Difficult asthma. London: Dunitz Martin Ltd; 1999.
(check this in PDF content)
3
Аверьянов А.В., Чучалин А.Г., Поливанова А.Э. и др. Фе$ нотипы больных хронической обструктивной бо$ лезнью легких. Тер. арх. 2009; 3: 9–15.
(check this in PDF content)
4
Garcia2Aymerich J., Agusti A., Barbera J. A. et al.Phenotypic heterogeneity of chronic obstructive pulmonary disease. Arch. Bronconeumol. 2009; 45 (3): 129–138.
(check this in PDF content)
5
Огородова Л.М., Кобякова О.С., Петровская Ю.А. и др. Сложная астма. Пульмонология 2001; 1: 94–100.
(check this in PDF content)
6
Огородова Л.М., Кобякова О.С., Петровский Ф.И. и др. Клинико$функциональная характеристика фенотипов тяжелой неконтролируемой бронхиальной астмы. Клин. мед. 2006; 2: 24–27.
(check this in PDF content)
7
Sato E., Koyama S., Okubo Y. et al. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemo$ tactic activity. Am. J. Physiol. 1998; 274: 970–979.
(check this in PDF content)
8
Mita Y., Dobashi K., Suzuki K. et al. Induction of muscarinic receptor subtypes in monocytic / macrophagic cells differenti$ ated from EoL$1 cells. Eur. J. Pharmacol. 1996; 297: 121–127.
(check this in PDF content)
9
Lambrecht B.N., Hoogsteden H.C., Diamant Z., ed. The immunological basis of asthma (Lung Biology in Health and Disease. Vol. 174.). New York: Marcel Dekker; 2003.
(check this in PDF content)
10
Hall I.P. Beta2$adrenoceptor polymorphisms and asthma. Clin. Exp. Allergy 1999; 29 (9): 1151–1154.
(check this in PDF content)
11
Sarika G.S., Awasthi S.Pharmacogenomics of pediatric asthma. Indian J. Hum. Genet. 2010; 16 (3): 111–118.
(check this in PDF content)
12
Yamamoto T., Yamashita N., Kuwabara M. et al. Mutation screening of the muscarinic M2 and M3 receptor genes in asthmatics, outgrow subjects, and normal controls. Ann. Genet. 2002; 45: 109–113.
(check this in PDF content)
13
Fenech A.G., Ebejer M.J., Felice A.E. et al. Mutation screen$ ing of the muscarinic M2 and M3 receptor genes in normal and asthmatic subjects. Br. J. Pharmacol. 2001; 133: 43–48.
(check this in PDF content)
14
The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from: http:// www.goldcopd.org
(check this in PDF content)
15
The Global Strategy for Asthma Management and Preven$ tion, Global Initiative for Asthma (GINA) 2010. Available from: http:// www.ginasthma.org
(check this in PDF content)
16
Wenzel S. Severe asthma in adults. Am. J. Respir. Crit. Care Med. 2005; 172: 149–160.
(check this in PDF content)
17
Moore W.C., Meyers D.A., Wenzel S.E.Identification of asthma phenotypes using cluster analysis in the severe asth$ ma research program. Am. J. Respir. Crit. Care Med. 2010;
(check this in PDF content)
18
315–323. 18.Bradding P., Green R.H. Subclinical phenotypes of asthma. Curr. Opin. Allergy Clin. Immunol. 2010; 10 (1): 54–59.
(check this in PDF content)
19
Трофименко И.Н., Черняк Б.А. Бронхиальная гиперре$ активность как фенотипическая характеристика хро$ нической обструктивной болезнью легких. Пульмоно$ логия 2011; 4: 49–53.
(check this in PDF content)
20
Marco R., Accordini S., Marcon A. et al.Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am. J. Respir. Crit. Care Med. 2011; 183 (7): 891–897.
(check this in PDF content)
21
Hospers J.J., Postma D.S., Rijcken B. et al.Histamine airway hyper$responsiveness and mortality from chronic obstruc$ tive pulmonary disease: a cohort study. Lancet 2000; 356: 1313–1317.
(check this in PDF content)
22
Kanner R.E., Connett J.E., Altose M.D. et al.Gender differ$ ence in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am. J. Respir. Crit. Care Med. 1994; 150 (4): 956–961.
(check this in PDF content)
23
Yang S.C., Lin B.Y.Comparison of airway hyperreactivity in chronic obstructive pulmonary disease and asthma. Chang Gung Med. J. 2010; 33: 515–523.
(check this in PDF content)
24
Selivanova P.A., Kulikov E.S., Kozina O.V. et al. Morpho$ logical and molecular characteristics of "difficult" asthma. J. Asthma 2010; 47 (3): 269–275.
(check this in PDF content)
25
Геренг Е.А., Суходоло И.В., Огородова Л.М. и др. Роль клеточных и молекулярных мишеней в формировании различных паттернов воспаления при гетерогенных фенотипах тяжелой бронхиальной астмы. Пульмоно$ логия 2009; 5: 78–82.
(check this in PDF content)
26
Огородова Л.М., Селиванова П.А., Геренг Е.А. и др. Пато$ морфологическая характеристика нестабильной брон$ хиальной астмы (фенотип brittle). Тер. арх. 2008; 3: 39–43.
(check this in PDF content)
27
Barnes P.J.Beta$adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 1995; 152 (3): 838–860.
(check this in PDF content)
28
Fraser C.M., Chung F.Z., Wang C.D. et al. Site$directed mutagenesis of human beta$adrenergic receptors: substitu$ tion of aspartic acid$130 by asparagine produces a receptor with high$affinity agonist binding that is uncoupled from adenylate cyclase. Proc. Natl. Acad. Sci. USA 1988; 85 (15): 5478–5482.
(check this in PDF content)
29
Dishy V., Landau R., Sofowora G.G. et al.Beta2$adrenocep$ tor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensi$ tivity in vivo. Pharmacogenetics 2004; 14 (8): 517–522.
(check this in PDF content)
30
Hizawa N., Makita H., Nasuhara Y. et al. Beta2$adrenergic receptor genetic polymorphisms and short$term bron$ chodilator responses in patients with COPD. Chest 2007; 132 (5): 1485–1492.
(check this in PDF content)
31
Kim W.J., Hersh C.P., DeMeo D.L. et al.Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respir. Med. 2009; 103 (4): 552–557.
(check this in PDF content)
32
O'Donnell D.E., Fluge T., Gerken F. et al.Effects of tiotropi$ um on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23 (6): 832–840.
(check this in PDF content)
33
Barnes P.J., Belvisi M.G., Mak J.C. et al. Tiotropium bro$ mide (Ba 679 BR), a novel long$acting muscarinic antago$ nist for the treatment of obstructive airways disease. Life Sci. 1995; 56 (11–12): 853–859. Передовая статья
(check this in PDF content)
34
Трофименко И.Н., Непомнящих Н.В., Черняк Б.А. Влия$ ние тиотропия бромида и формотерола на гиперреак$ тивность бронхов при ХОБЛ. В кн.: XXI Националь$ ный конгресс по болезням органов дыхания: Сборник трудов. М.: Дизайн Пресс; 2011. 97.
(check this in PDF content)
35
Subramaniam K., Chen K., Joseph K. et al. The 3'$untrans$ lated region of the beta2$adrenergic receptor mRNA regu$ lates receptor synthesis. J. Biol. Chem. 2004; 279 (26): 27108–27115.
(check this in PDF content)
36
Moore P.E.Exploration of the beta2$adrenergic receptor regulatory regions: the next step in the holy grail of asthma pharmacogenetics research. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008; 294 (2): L187– L189. Информация об авторах
(check this in PDF content)